Inspirna, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.rgenix.com
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Inspirna, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05983367
- Locations
- ๐ง๐ช
Imelda Ziekenhuis, Bonheiden, Antwerpen, Belgium
๐ง๐ชUniversite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Brussels Capital Region, Belgium
๐ง๐ชInstitut Jules Bordet, Anderlecht, Belgium
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Inspirna, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT03597581
- Locations
- ๐บ๐ธ
Cedars-Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธThomas Jefferson, Philadelphia, Pennsylvania, United States
๐บ๐ธDartmouth, Lebanon, New Hampshire, United States
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Inspirna, Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT02922764
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธThomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
๐บ๐ธSarah Cannon Research Institute, Denver, Colorado, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath